Despite this wealth of evidence that NK-1/substance P signaling forms a growth-driving element across a wide variety of cancers, aprepitant’s only clinical use so far has been its use in treating glioblastoma where preliminary evidence indicates a survival advantage from its use in the ten-drug CUSP9v3 protocol for treating glioblastoma [9]. This evidence concerns the gene TAC1 and glioblastoma.